Skip to search formSkip to main contentSkip to account menu

SY-1425

National Institutes of Health

Related topics

Related topics

1 relation
Am 80

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Introduction: SY-1425 (tamibarotene) is an orally available, synthetic retinoid in Phase 2 development for non-APL AML and MDS… 
2017
2017
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following…
2017
2017
Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.
In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in… 
2017
2017
A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
TPS7071Background: SY-1425 (tamibarotene) is an orally available, synthetic retinoid approved in Japan for the treatment of… 
2017
2017
Abstract 3085: SY-1425 (tamibarotene), a selective RARα agonist, shows synergistic anti-tumor activity with hypomethylating agents in a biomarker selected subset of AML
In patients with acute myeloid leukemia (AML) (≥ 60 years) and myelodysplastic syndrome (MDS), the use of hypomethylating agents… 
2017
2017
Abstract P6-11-18: A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor α agonist treatment
Endocrine-resistance remains a major challenge for treatment of breast cancer. Multiple mechanisms for endocrine resistance have… 
2017
2017
Abstract 1511: AML patient clustering by super-enhancers reveals an RARA associated transcription factor signaling partner
Prior studies have shown that the RARA gene is associated with a super-enhancer (SE) and has upregulated mRNA expression in a… 
2016
2016
Abstract 1187: Discovery of new AML and MDS patient subsets sensitive to the highly selective RARα agonist SY-1425 (tamibarotene) through super-enhancer analysis
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)